

Studienarchiv

Eudara-CT Sponsor	Studienbezeichnung	Phase von bis Status	PI
2007-00283-73 GSK	MAGRIT: MAGE-A3 as Adjuvant Non-Small Cell Lung Cancer ImmunoTherapy	III 2008 2014 beendet	Voshaar Kambartel Yildirim
2008-002144-42 GSK	VEG111128: An open-label, multicentre, randomised phase II study of pazopanib in combination with pemetrexed in first-line treatment of subjects with predominantly non-squamous cell stage IIIBwet/IV non-small cell lung cancer	II 2008 2009 beendet	Voshaar Kambartel Yildirim
2012-0027900-55 GSK	PEARL: PRAME as Adjuvant immunotherapy in Resected Non-Small Cell Lung Cancer	I/II 2012 2014 beendet	Kambartel Voshaar
2010-022656-22 Pfizer	ARCHER 1009: A randomized double blind Phase 3 efficacy and safety Study of PF-00299804 (Dacomitinib) versus Erlotinib for the Treatment of advanced Non-Small Cell Lung Cancer following Progression after, or Intolerance to, at least one prior Chemotherapy	III 2012 09.11.15 beendet	Voshaar Kambartel
2012-003622-25 Astra	"Study 64": A Phase II, Double-Blind, Randomised, Placebo-Contralled Study to Assess the Efficacy and Safty of Selumetinib (AZD6244) in Combination with Docetaxel, Compared with Placebo in Combination with Docetaxel, in Patients receiving second line treatment for locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV)	II 2013 10.05.16 beendet	Voshaar Kambartel
2011-001161-41 GSK / Novartis	BRF113928: A Phase II study of the selective BRAF kinase inhibitor GSK2118436 in subjects with advanced non-small cell lung cancer and BRAF mutations	II 13.03.14 10.08.16 beendet	Kambartel Yildirim



2013-001676-38 Astra	SELECT-1: A Phase III, Double Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safty of Selumetinib in Combination with Docetaxel, in Patients receiving second line treatment for KRAS Mutation positive Locally Advanced or Metastatic NSCLC (Stage IIIb-IV)	III 29.01.14 04.10.16 beendet	Kambartel Voshaar
DRKS00004897 IT	SevLoT1a: Randomized, multicenter phase III trial to compare anatomical segmentomy plus radical lymphadenectomy versus standard lobectomy plus radical lymphadenectomy in patients with Non Small Cell Lung Cancer (NSCLC) up to 2cm diameter (pT1a pN0 cM0, Stage Ia) concerning overall-survival, quality of life and complications ()	III geschlossen	Krbek Kopeika
ML23023 Roche	Eldertac ML23023	IV 11.08.11 13.04.15 beendet	Voshaar Kambartel
	ASORS Antiemese	IV beendet	Kambartel
D1532R00004 Astra	LUMINIST: Lung cancer Molecular Insights Non Interventional Study	IV 26.02.15 31.03.16 beendet	Kambartel Voshaar
MK3475-3396 Merk	PivOTAL study: Global treatment patterns, resource utilization and BiOmarker Testing in Advanced non-small cell Lung cancer.	IV 16.10.15 26.08.16 beendet	Kambartel Voshaar
2014-003878-16 Pfizer	A Phase 3 Randomised, Doubel-blind Study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizimab plus Paclitaxel-Carboplatin for the First Line Treatment of Patients with Advanced Non-Squamous-Non-Small-Cell Lung-Cancer (NSCLC)	III 12/15 beendet	Wiegand Eggert
2015-001123-22 AIO- Studien-gGmbH	AIO-TRK-0115 PRIMUS: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients with Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)	II 28.01.16 21.07.21 beendet	Kambartel Voshaar Yildirim



2016-003334-25 Uni Köln	BIOLUMA: A phase II trial of nivolumab and sequential ipilimumab to evaluate efficacy and safety in nivolumab-refractory relapsed non-squamous non-small cell lung cancer (NSCLC) and to evaluate biomarkers predictive for response to checkpoint inhibition	II 2017 05.11.19 beendet	Kambartel Voshaar Yildirim
NCT02713867 BMS	CheckMate 384 (CA209-384);+B18:B23 A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks	III 22.09.2016 03.03.2021 beendet	Kambartel Voshaar Yildirim
NCT02899299 BMS	Ckeckmate 743 (CA209-743) A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable Pleural Mesothelioma	III 2017 16.10.2023 beendet	Kambartel Voshaar Yildirim
NCT03631784 MSD	KEYNOTE-799 A Phase II Trial of Pembrolizumab in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III NSCLC	II geschlossen	Kambartel Voshaar Yildirim
NCT02622581 AIO- Studien-gGmbH	AIO-TRK-0315: Clinical Research Platform Into Molecular Testing, Treatment and Outcome of Non-Small Cell Lung Carcinoma Patients (CRISP) (Stadium III)	IV beendet	Kambartel Voshaar
NCT02910999 BMS	Enlarge Lung Eine nationale, prospektive, nicht-interventionelle Studie (NIS) mit Nivolumab bei Patienten mit lokal fortgeschrittenem oder metastasiertem, nicht-kleinzelligen Lungenkarzinom (NSCLC) mit plattenepithelialer oder nicht-plattenepithelialer Histologie (Stadien IIIB/IV) nach vorheriger Chemotherapie	IV geschlossen bis 2019	Wiegand
NCT03559647 Roche	Hyperion-NIS Nichtinterventionelle Studie zur Untersuchung der Wirksamkeit von Atezolizumab in der alltäglichen Praxis bei Patienten mit Lokal fortgeschrittenem oder metastasiertem NSCLC nach vorheriger Chemotherapie	IV geschlossen seit 2019	Wiegand
EudraCT Nr. 2017- 001723-45 AIO-Studie	AIO-TRK-0117, NintNivo Machbarkeit und Sicherheit von Nintedanib in Kombination mit Nivolumab bei vorbehandelten Patienten mit fortgeschrittenem oder metastasiertem nicht-kleinzelligem Lungenkarzinom (NSCLC) mit Adenokarzinom-Histologie	Ib beendet 14.09.19 14.06.23	Kambartel Voshaar Yildirim



EUDRACT 2019-000262-38 BMS	CheckMate 77T A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer	III geschlossen 24.01.20	Kambartel Voshaar Yildirim
EUDRACT 2019-003582-18 Amgen	AMG-510 20190009 A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C	III beendet	Kambartel Voshaar Yildirim
Amgen	AMG-510 20190294 A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Non-Small Cell Lung Cancer (NSCLC)	IV beendet	Kambartel Voshaar Yildirim
EUDRACT 2020-000633-40 Janssen-Cilag	61186372NSC3001 (PAPILLON) A randomized, open-label, phase 3 study of combination JNJ-61186372 and Carboplatin-Pemetrexed therapy, compared with Carboplatin-Pemetrexed, in patients with EGFR Exon 20ins-mutated locally advanced or Metastatic Non-Small Cell Lung Cancer	III beendet 06.12.22	Kambartel Voshaar Yildirim
EUDRACT 2021-001825-33 Janssen-Cilag	A Phase 3, open label, randomized study of Amivantamab and Lazertinib in combination with Platinum-Based Chemotherapie compared with Platinum-Based Chemotherapie in Patients with EGFR-Mutated Locally Advanced or metastatic NSCLC after Osimertinib (Mariposa-2)	III 06.12.22 geschlossen	Kambartel Voshaar Yildirim
2021-003254-23 RMC-Medicine	A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRASG12C Mutation After Failure of Prior Standard Therapies	II 10.10.22 22.12.23 beendet	Kambartel Voshaar Yildirim